How biotech investors can profit from an ageing population and the future of medicine

The wealthy western world’s population is ageing and medicine is changing fast. Biotechnology lies at the intersection of this growing need for healthcare and treatments that are tailored to patients, such as immunotherapy, rather than taking a traditional one size fits all approach. Investors’ excitement for this brave new world saw many biotech fund and trusts deliver startling performance from 2012 to 2016 before the sector then suffered a fall, as the last US election brought worries to the fore. Things have begun to look up again for biotech over the past year and we are joined on this Investing Show by Ailsa Craig, of International Biotechnology Trust, to find out more about this and the sector.